データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます
64953-12-4CO[C@@]1(NC(=O)C(C(=O)[O-])c2ccc(O)cc2)C(=O)N2C(C(=O)[O-])=C(CSc3nnnn3C)CO[C@@H]21.[Na+].[Na+]GRIXGZQULWMCLU-HUTAOCTPSA-L64953-12-4DTXSID0045595CHEMBL1200357安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。
説明Latamoxef was synthesized by Shionogi Pharmaceuticals in 1975 starting with benzylpenicillin and using a novel drug design. The oxacephem nucleus, in which the sulfur atom had been replaced by oxygen, was substituted with a methoxyl group at the 7α position, as in the cephamycins. A carboxyl moiety and a hydroxybenzyl group were added at the 7β position, as in carbenicillin, and a methyltetrazolylthiomethyl group was attached at the 3 position. These substitutions resulted in a strong activity against gram-negative bacteria and a high resistance to the action of βlactamase, along with excellent activity against Pseudomonas aeruginosa, even though the compound has no activity against Staphylococcus aureus.
使用Moxalactam Sodium is an oxacephem antibiotic. Moxalactam Sodium is more effective against Escherichia coli and Pseudomonas aeruginosa than cephalosporins.
読み込み中…
読み込み中…
現在のフィルター条件では反応記録がありません。
読み込み中…